Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences ...

Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop tomorrows genetic therapies.

Roger Cone, Ph.D., a professor at the University of Michigan and the founder and chair of the scientific advisory board at Courage Therapeutics, has been thinking about the biological mechanics of ...

As biotech companies face decreasing productivity, they need ways to do more with less, and fast. A fresh approach to achieve this is by rethinking how innovation is structured: collaborate early and ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

In the early 1990s, my grandmother’s health and cognitive abilities started to decline rapidly. She showed clear signs of dementia, which was most likely Alzheimer’s disease but never received a ...

In most life sciences companies, commercial teams are pulled into BD conversations, but often the depth of evaluation falls short of making real impact. By the time we’re asked to weigh in, key ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...